Rivaroxaban: A once-daily anticoagulant for the prevention of thromboembolic complications

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 2, 2013, Pages 129-141

  Barrios, Vivencio ^a   Escobar, Carlos ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

atrial fibrillation; deep vein thrombosis; ischemic heart disease; medication adherence; once daily; pulmonary embolism; renal insufficiency; rivaroxaban; venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; CARBAMAZEPINE; CLARITHROMYCIN; DABIGATRAN; DRONEDARONE; EDOXABAN; ENOXAPARIN; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; RIFAMPICIN; RIVAROXABAN; VORICONAZOLE; WARFARIN;

ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; EMBOLISM; EMBOLISM PREVENTION; ETHNIC DIFFERENCE; FOLLOW UP; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; LONG TERM CARE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MEDICATION ADHERENCE; MORPHOLINES; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; STROKE; THIOPHENES; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84873913233     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.172     Document Type: Review

References (84)

1. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am. J. Cardiol. 74(3), 236-241 (1994).
2. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18), 2370-2375 (2001).
3. Barrios V, Calderón A, Escobar C, de la Figuera M; Primary Care Group in the Clinical Cardiology Section of the Spanish Society of Cardiology. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev. Esp. Cardiol. (Engl.) 65(1), 47-53 (2012).
4. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation -executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J. Am. Coll. Cardiol. 48(4), 854-906 (2006).
5. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am. J. Med. 98(5), 476-484 (1995).
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8), 983-988 (1991).
7. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 254(24), 3449-3453 (1985).
8. Lévy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 99(23), 3028-3035 (1999).
9. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271(11), 840-844 (1994).
10. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can. J. Cardiol. 27(1), 74-90 (2011).
11. Skanes AC, Healey JS, Cairns JA et al.; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28(2), 125-136 (2012).
12. Wann LS, Curtis AB, Ellenbogen KA et al.; American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 123(10), 1144-1150 (2011).
13. You JJ, Singer DE, Howard PA et al.; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl. 2), e531S-e575S (2012).
14. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the european society of cardiology (ESC). Eur. Heart J. 31(19), 2369-2429 (2010).
15. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2), 263-272 (2010).
16. Jover E, Roldán V, Gallego P et al. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev. Esp. Cardiol. (Engl.) 65(7), 627-633 (2012).
17. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146(12), 857-867 (2007).
18. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst. Rev. (3), CD006186 (2007).
19. Raunsø J, Selmer C, Olesen JB et al. Increased short-term risk of thromboembolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur. Heart J. 33(15), 1886-1892 (2012).
20. Escobar C, Barrios V, Jimenez D. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants? Cardiovasc. Ther. 28(5), 295-301 (2010).
21. Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood 105(2), 453-463 (2005).
22. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349(11), 1019-1026 (2003).
23. Mangiafico RA, Mangiafico M. Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. Curr. Med. Chem. 19(27), 4688-4698 (2012).
24. Carag MR, Arora RR. The efficacy of rivaroxaban in patients with atrial fibrillation. Am. J. Ther. doi: 10.1097/ MJT.0b013e3182491d8b (2012) (Epub ahead of print).
25. Prasad V, Kaplan RM, Passman RS. New frontiers for stroke prevention in atrial fibrillation. Cerebrovasc. Dis. 33(3), 199-208 (2012).
26. Poldermans D, Bax JJ, Boersma E et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in noncardiacsurgery: the Task Force for preoperative cardiac risk assessment and perioperative cardiac management in noncardiac surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur. Heart. J. 30(22), 2769-2812 (2009).
27. Patel MR, Mahaffey KW, Garg J et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883-891 (2011).
28. Connolly SJ, Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009).
29. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 320(7244), 1236-1239 (2000).
30. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am. J. Med. 123(7), 638-645.e4 (2010).
31. Pinto DJ, Qiao JX, Knabb RM. The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review. Expert Opin. Ther. Pat. 22(6), 645-661 (2012).
32. Morales-Vidal S, Schneck MJ, Flaster M, Biller J. Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. Expert Rev. Neurother. 12(2), 179-189; quiz 190 (2012).
33. Kreutz R. Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fundam. Clin. Pharmacol. 26(1), 27-32 (2012).
34. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin. Pharmacokinet. 50(10), 675-686 (2011).
35. Xu XS, Moore K, Burton P et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. Br. J. Clin. Pharmacol. 74(1), 86-97 (2012).
36. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am. Heart. J. 159(3), 340-347 (2010).
37. Tanigawa T, Kaneko M, Hashizume K et al. Model-based dose selection for Phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab. Pharmacokinet. doi:10.2133/dmpk.DMPK-12-RG-034 (2012) (Epub ahead of print).
38. Japanese Circulation Society Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ. J. 74(11), 2479-2500 (2010).
39. Hori M, Matsumoto M, Tanahashi N et al.; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation -the J-ROCKET AF study. Circ. J. 76(9), 2104-2111 (2012).
40. Hankey GJ, Patel MR, Stevens SR et al.; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 11(4), 315-322 (2012).
41. Barrios V, Escobar C, Murga N et al. Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice. J. Hypertens. 26(11), 2230-2235 (2008).
42. Hart RG, Eikelboom JW, Ingram AJ, Herzog CA. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat. Rev. Nephrol. 8, 569-578 (2012).
43. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N. Engl. J. Med. 366(9), 864-866 (2012).
44. Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur. Heart J. 32(19), 2387-2394 (2011).
45. Barrios V, Escobar C, Bertomeu V, Murga N, de Pablo C, Calderón A. [Risk factor control in the hypertensive patients with chronic ischemic heart disease attended in cardiologic outpatient clinics. The CINHTIA study]. Rev. Clin. Esp. 208(8), 400-404 (2008).
46. Barrios V, Escobar C, Echarri R. Atrial fibrillation and coronary heart disease: fatal attraction. J. Atr. Fibrillation. 1(5), 262-269 (2009).
47. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N. Engl. J. Med. 363(19), 1875-1876 (2010).
48. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb. Haemost. 107(3), 584-589 (2012).
49. De Caterina R, Husted S, Wallentin L et al.; Coordinating Committee. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-Task Force on anticoagulants in heart disease position paper. J. Am. Coll. Cardiol. 59(16), 1413-1425 (2012).
50. Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace 13(10), 1375-1385 (2011).
51. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 9(5), 348-356 (2006).
52. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am. J. Cardiol. 110(6), 845-851 (2012).
53. Deitelzweig S, Amin A, Jing Y et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J. Med. Econ. 15(4), 776-785 (2012).
54. Agnelli G, Gallus A, Goldhaber SZ et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 116(2), 180-187 (2007).
55. Buller HR, Lensing AW, Prins MH et al.; Einstein-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 112(6), 2242-2247 (2008).
56. Ogata K, Mendell-Harary J, Tachibana M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J. Clin. Pharmacol. 50(7), 743-753 (2010).
57. Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 160(4), 635-641 (2010).
58. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120(8), 713-719 (2007).
59. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag. Care. 9(Suppl. 9), 2-6 (2000).
60. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am. J. Cardiovasc. Drugs 8(1), 45-50 (2008).
61. Frishman WH. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Cardiol. Rev. 15(5), 257-263 (2007).
62. Cohen AT, Dobromirski M. The use of rivaroxaban for short-and long-term treatment of venous thromboembolism. Thromb. Haemost. 107(6), 1035-1043 (2012).
63. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Adv. Hematol. 2012, 856341 (2012).
64. Cohen AT, Agnelli G, Anderson FA et al.; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb. Haemost. 98(4), 756-764 (2007).
65. Eriksson BI, Borris LC, Friedman RJ et al.; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358(26), 2765-2775 (2008).
66. Kakkar AK, Brenner B, Dahl OE et al.; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632), 31-39 (2008).
67. Lassen MR, Ageno W, Borris LC et al.; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358(26), 2776-2786 (2008).
68. Turpie AG, Lassen MR, Davidson BL et al.; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676), 1673-1680 (2009).
69. Cohen AT, Spiro TE, Büller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J. Thromb. Thrombolysis 31(4), 407-416 (2011).
70. Cohen AT; on behalf of the MAGELLAN Steering Committee and Investigators. LBCT IV Session 3015. Presented at: The 60th American College of Cardiology Annual Scientific Sessions. New Orleans, LA, USA, 2-5 April 2011.
71. Bauersachs R, Berkowitz SD, Brenner B et al.;EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363(26), 2499-2510 (2010).
72. Büller HR, Prins MH, Lensin AW et al.; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366(14), 1287-1297 (2012).
73. Mega JL, Braunwald E, Wiviott SD et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366(1), 9-19 (2012).
74. Alexander JH, Lopes RD, James S et al.; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med. 365(8), 699-708 (2011).
75. Oldgren J, Budaj A, Granger CB et al.; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, Phase II trial. Eur. Heart J. 32(22), 2781-2789 (2011).
76. Granger CB, Alexander JH, McMurray JJ et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981-992 (2011).
77. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation -developed with the special contribution of the European Heart Rhythm Association. Eur. Heart. J. 33(21), 2719-2747 (2012).
78. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124(14), 1573-1579 (2011).
79. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb. Haemost. 108(2), 217-224 (2012).
80. Kaatz S, Kouides PA, Garcia DA et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am. J. Hematol. 87(Suppl. 1), S141-S145 (2012).
81. Barrios V, Escobar C, Echarri R. Importance of medication adherence from the ONTARGET and TRANSCEND points of view. Fundam. Clin. Pharmacol. 23(2), 259-260 (2009).
82. Mancia G, Omboni S, Grassi G. Combination treatment in hypertension: the VeraTran Study. Am. J. Hypertens. 10(7 Pt 2), 153S-158S (1997).
83. European Medicines Agency (EMA). Xarelto®, Summary of Product Characteristics. www.ema.europa.eu /docs /en-GB/ document-library /EPAR-Product -Information /human/000 944/ WC500057108.pdf (Accessed 20 January 2012)
84. European Medicines Agency (EMA). Pradaxa®, Summary of Product Characteristics. www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product- Information/ human/000829/ WC500041059.pdf (Accessed 20 March 2012)